MRI与彩超对局部晚期乳腺癌新辅助化疗的临床效果评价

MRI and Color Doppler Ultrasound for Evaluating the Response of Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients

目的探讨MRI与彩超在评价局部晚期乳腺癌新辅助化疗临床效果中的作用。方法选取我院收治局部晚期乳腺癌患者63例为研究对象,患者采取新辅助化疗,化疗降期后采取手术治疗,依照手术方法不同分为保乳术组和改良根治术组,改良根治术组行全乳切片病理检查,保乳术组行乳腺切缘、乳头切缘及瘤床病理切片并与化疗前后影像学变化进行比较。结果 MRI、彩超测得肿瘤最大径与病理误差较少,MRI与病理测得值关联性最好,MRI测得的肿瘤最大径与病理测得值误差小于彩超。患者术后病理体积大小为(9.65±2.84)mm3,与化疗后肿瘤MRI体积大小(9.62±2.37)mm3比较,无明显差异(P>0.05),术后病理体积大小显著小于化疗前肿瘤MRI体积,(41.62±56.27)mm3(P<0.05)。结论局部晚期肿瘤乳腺癌患者采用MRI诊断能够较高地评估肿瘤形态,与彩超相比,能够更加准确地为新辅助化疗方案的疗效评价提供依据。

Objective To analyze MRI and color doppler ultrasound for evaluating the response of neoadjuvant chemotherapy in locally advanced breast cancer patients. Methods 63 patients with locally advanced breast cancer in our hospital were enrolled,who were taken treatment of neoadjuvant chemotherapy followed by surgical treatment. Patients were divided into conserving surgery group and modified radical mastectomy group. The latter group received the whole breast pathological test and analyzed the iconographic change before and after chemotherapy. And the imaging data was compared with the pathological results. Results There was no difference of the tumor size measured by MRI or color doppler ultrasound,comparing with the pathological result. The correlation of MRI and pathologic results was best. Postoperative pathology volume size was( 9. 65 ± 2. 84) mm3,which had no significant difference between MRI after chemotherapy tumor volume size,( 9. 62 ± 2. 37) mm3( P > 0. 05). And the pathological volume size was significantly smaller than MRI tumor volume before chemotherapy,( 41. 62 ± 56. 27) mm3( P < 0. 05). Conclusion Compared with color doppler ultrasound,MRI can provide better tumor image and more accurate information about the effect of the neoadjuvant chemotherapy in patients with locally advanced breast cancer.